Streetbeat News

Stock Prices

RYTM

Rhythm Pharmaceuticals (NASDAQ:RYTM) has dosed the first patients in its Phase 2 trial for LB54640, an oral MC4R agonist, targeting hypothalamic obesity. The drug has shown targeted effects without causing hyperpigmentation.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:14 pm

MOBX

Mobix Labs has announced the issuance and sale of 2.88 million shares of Class A common stock and warrants in a $4 million private placement. The Series A and B warrants are priced at $1.39 per share, pending stockholder approval, with the closing expected on July 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:14 pm

KNSA

Kiniksa Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY24 net product revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:13 pm

DHR

TMO

Thermo Fisher shares are trading higher in possible sympathy with Danaher, which reported better-than-expected Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:13 pm

MDAI

Spectral AI, Inc. (NASDAQ:MDAI) has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study, increasing the total number to 16. The new sites include University Medical Center Burn Center at Texas Tech University Health Sciences Center, Tampa General Hospital Burn Center, and University of South Alabama Health Emergency Department.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:13 pm

AZTR

Azitra, Inc. (NYSE:AZTR) has strengthened its global intellectual property portfolio with newly granted and allowed patents in the U.S., China, and Canada. These patents protect a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of atopic dermatitis and other skin diseases. This development broadens Azitra's IP position for its precision dermatology platform.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:12 pm

KMB

Kimberly-Clark shares are trading lower following mixed Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:11 pm

JAGX

Jaguar Health announced that its OnTarget study, a multicenter, double-blind, placebo-controlled pivotal clinical trial, did not meet its primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:11 pm

JAGX

Jaguar Health has announced a webcast on July 23 to discuss the Phase 3 OnTarget trial results for Crofelemer. The webcast will also include updates on their cancer supportive care portfolio and the expansion of the Make Cancer Less Shitty (MCLS) program with new ambassadors.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:09 pm

TSLA

Tesla shares rose in premarket trading ahead of its Q2 earnings report. Analysts have increased their estimates following better-than-expected delivery numbers. The key metric to watch is the auto gross margin, excluding regulatory credits. The earnings call will provide insights into Tesla's future direction, including robotaxis and full self-driving technology.

Portfolio Pulse from Shanthi Rexaline

July 23, 2024 | 12:08 pm